WO2010026110A3 - Benzoxazines à substitution en 6 - Google Patents
Benzoxazines à substitution en 6 Download PDFInfo
- Publication number
- WO2010026110A3 WO2010026110A3 PCT/EP2009/061152 EP2009061152W WO2010026110A3 WO 2010026110 A3 WO2010026110 A3 WO 2010026110A3 EP 2009061152 W EP2009061152 W EP 2009061152W WO 2010026110 A3 WO2010026110 A3 WO 2010026110A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disorders
- receptor antagonists
- present
- substituted benzoxazines
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES09782348T ES2394766T3 (es) | 2008-09-08 | 2009-08-28 | Benzoxazinas 6-sustituidas como antagonistas del receptor 5-ht-5a |
BRPI0918068A BRPI0918068A2 (pt) | 2008-09-08 | 2009-08-28 | benzoxazinas 6-substituídas |
CA2735775A CA2735775A1 (fr) | 2008-09-08 | 2009-08-28 | Benzoxazines a substitution en 6 |
CN2009801350989A CN102149697A (zh) | 2008-09-08 | 2009-08-28 | 作为5-ht-5a受体拮抗剂的6-取代的苯并*嗪 |
AU2009289305A AU2009289305B2 (en) | 2008-09-08 | 2009-08-28 | 6-substituted benzoxazines as 5-HT-5A receptor antagonists |
JP2011525514A JP5368566B2 (ja) | 2008-09-08 | 2009-08-28 | 5−th−5a受容体アンタゴニストとしての6−置換ベンゾオキサジン |
MX2011001926A MX2011001926A (es) | 2008-09-08 | 2009-08-28 | Benzoxazinas 6-sustituidas. |
EP09782348A EP2328880B1 (fr) | 2008-09-08 | 2009-08-28 | Benzoxazines 6-substitues en tant qu'antagonistes des recepteurs 5-ht-5a |
IL210927A IL210927A0 (en) | 2008-09-08 | 2011-01-27 | 6-substituted benzoxazines as 5-ht-5a receptor antagonists |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08163833.0 | 2008-09-08 | ||
EP08163833 | 2008-09-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010026110A2 WO2010026110A2 (fr) | 2010-03-11 |
WO2010026110A3 true WO2010026110A3 (fr) | 2010-05-27 |
Family
ID=41381608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/061152 WO2010026110A2 (fr) | 2008-09-08 | 2009-08-28 | Benzoxazines à substitution en 6 |
Country Status (12)
Country | Link |
---|---|
US (1) | US8163740B2 (fr) |
EP (1) | EP2328880B1 (fr) |
JP (1) | JP5368566B2 (fr) |
KR (1) | KR20110038179A (fr) |
CN (1) | CN102149697A (fr) |
AU (1) | AU2009289305B2 (fr) |
BR (1) | BRPI0918068A2 (fr) |
CA (1) | CA2735775A1 (fr) |
ES (1) | ES2394766T3 (fr) |
IL (1) | IL210927A0 (fr) |
MX (1) | MX2011001926A (fr) |
WO (1) | WO2010026110A2 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5368567B2 (ja) * | 2008-09-08 | 2013-12-18 | エフ.ホフマン−ラ ロシュ アーゲー | 5−置換ベンゾオキサジン |
MX2015004989A (es) * | 2012-10-26 | 2015-07-17 | Procter & Gamble | Proceso para preparar 2-metoximetil-1,4-bencenodiamina y sales de esta. |
US9012691B2 (en) * | 2012-10-26 | 2015-04-21 | The Procter & Gamble Company | Process for preparing primary intermediates for dyeing keratin fibers |
CN110872281B (zh) * | 2019-11-29 | 2024-02-27 | 淮北绿洲新材料有限责任公司 | 一种叔酚-糠胺型苯并噁嗪单体、固化树脂及其共聚树脂的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003045313A2 (fr) * | 2001-11-27 | 2003-06-05 | Merck & Co. Inc. | Composés de 2-aminoquinoline |
WO2007022946A1 (fr) * | 2005-08-21 | 2007-03-01 | Abbott Gmbh & Co. Kg | Composes heterocycliques et leur utilisation en tant que partenaires de liaison des recepteurs 5-ht5 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0309781D0 (en) | 2003-04-29 | 2003-06-04 | Glaxo Group Ltd | Compounds |
BRPI0608729A2 (pt) * | 2005-03-15 | 2010-01-26 | Hoffmann La Roche | uso de 2-anilino-3,4-dihidro-quinazolinas como antagonistas de receptor 5ht5a |
KR100938297B1 (ko) * | 2005-04-11 | 2010-01-22 | 에프. 호프만-라 로슈 아게 | (3,4-다이하이드로-퀴나졸린-2-일)-인단-1-일-아민 |
JP4796624B2 (ja) * | 2005-05-04 | 2011-10-19 | エフ.ホフマン−ラ ロシュ アーゲー | 5−ht受容体に作用する(3,4−ジヒドロ−キナゾリン−2−イル)−(2−アリールオキシ−エチル)−アミン類 |
FR2888748B1 (fr) * | 2005-07-19 | 2007-10-12 | Biocodex | Composes neuroprotecteurs et compositions pharmaceutiques les comprenant |
-
2009
- 2009-08-28 EP EP09782348A patent/EP2328880B1/fr not_active Not-in-force
- 2009-08-28 ES ES09782348T patent/ES2394766T3/es active Active
- 2009-08-28 CA CA2735775A patent/CA2735775A1/fr not_active Abandoned
- 2009-08-28 AU AU2009289305A patent/AU2009289305B2/en not_active Ceased
- 2009-08-28 JP JP2011525514A patent/JP5368566B2/ja not_active Expired - Fee Related
- 2009-08-28 KR KR1020117005345A patent/KR20110038179A/ko not_active Application Discontinuation
- 2009-08-28 WO PCT/EP2009/061152 patent/WO2010026110A2/fr active Application Filing
- 2009-08-28 MX MX2011001926A patent/MX2011001926A/es active IP Right Grant
- 2009-08-28 BR BRPI0918068A patent/BRPI0918068A2/pt not_active IP Right Cessation
- 2009-08-28 CN CN2009801350989A patent/CN102149697A/zh active Pending
- 2009-08-28 US US12/549,745 patent/US8163740B2/en not_active Expired - Fee Related
-
2011
- 2011-01-27 IL IL210927A patent/IL210927A0/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003045313A2 (fr) * | 2001-11-27 | 2003-06-05 | Merck & Co. Inc. | Composés de 2-aminoquinoline |
WO2007022946A1 (fr) * | 2005-08-21 | 2007-03-01 | Abbott Gmbh & Co. Kg | Composes heterocycliques et leur utilisation en tant que partenaires de liaison des recepteurs 5-ht5 |
Also Published As
Publication number | Publication date |
---|---|
EP2328880A2 (fr) | 2011-06-08 |
ES2394766T3 (es) | 2013-02-05 |
AU2009289305A1 (en) | 2010-03-11 |
CN102149697A (zh) | 2011-08-10 |
US8163740B2 (en) | 2012-04-24 |
KR20110038179A (ko) | 2011-04-13 |
BRPI0918068A2 (pt) | 2015-12-01 |
IL210927A0 (en) | 2011-04-28 |
JP5368566B2 (ja) | 2013-12-18 |
MX2011001926A (es) | 2011-04-05 |
JP2012501993A (ja) | 2012-01-26 |
CA2735775A1 (fr) | 2010-03-11 |
US20100063037A1 (en) | 2010-03-11 |
WO2010026110A2 (fr) | 2010-03-11 |
AU2009289305B2 (en) | 2012-08-02 |
EP2328880B1 (fr) | 2012-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009109493A3 (fr) | 2-aminoquinolines | |
MX2009005509A (es) | 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a). | |
WO2008080844A9 (fr) | Dérivés azaspiro | |
WO2006119504A3 (fr) | Composes heterocycliques fusionnes, leurs compositions et leurs utilisations | |
JP2002523491A5 (fr) | ||
AR059183A1 (es) | Uso de derivados de 2- imidazol o imidazolina sustituidos para preparar medicamentos | |
WO2007141200A8 (fr) | Nouveaux dérivés de pyridinone substituée par n-aryle et n-hétéroaryle en vue d'une utilisation dans des maladies à médiation par mch-1 | |
WO2007076875A3 (fr) | Composes agissant sur le transporteur de la serotonine | |
WO2006044293A3 (fr) | Composes bicycliques utilises comme antagonistes du recepteur d'hormone concentrant la melanine selectifs destines au traitement de l'obesite et de troubles associes | |
WO2005080345A3 (fr) | Derives d'imidazoline a activite antagoniste cb1 | |
MX2009005507A (es) | Derivados de espiro-piperidina. | |
CY1110531T1 (el) | 6-υποκατεστημενες-2,3,4,5-τετραϋδρο-1η-βενζο[d]αζεπινες ως αγωνιστες του υποδοχεα 5-ht2c | |
JP2007520539A5 (fr) | ||
WO2007143523A3 (fr) | Sulfonamides tricycliques condensés inhibiteurs de gamma-secrétase | |
WO2010026110A3 (fr) | Benzoxazines à substitution en 6 | |
NO20073760L (no) | Triazolon-, tetrazolon- og imidazolonderivater for anvendelse som alfa-2C-adrenoreseptorantagonister | |
JP2007523206A5 (fr) | ||
MX2010009403A (es) | Derivados de 2-aminoquinolina. | |
WO2008077810A3 (fr) | Dérivés de spiropipéridine | |
JP2002525280A5 (fr) | ||
DE602007004881D1 (de) | Substituierte pyrazinonderivate zur verwendung als arzneimittel | |
GB0525069D0 (en) | Organic compounds | |
MX2009005544A (es) | Indoles. | |
MX2010009820A (es) | 2-aminoquinolinas como antagonistas del receptor 5-hidroxitriptamina 5a. | |
MX2009005541A (es) | Indoles que actuan como antagonistas del receptor v1a. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980135098.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09782348 Country of ref document: EP Kind code of ref document: A2 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2009782348 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009289305 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/001926 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2735775 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2009289305 Country of ref document: AU Date of ref document: 20090828 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1523/CHENP/2011 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20117005345 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2011525514 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: PI0918068 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110303 |